Table 2.
Guideline summary: cancer surveillance protocol for individuals with PTEN hamartoma tumour syndrome.
| Surveillance | Interval | From age | Evidence | |
|---|---|---|---|---|
| Breast cancer | MRI | Yearly | 30 | Strong |
| Mammography | Every 2 years | 40 | Moderate | |
| Risk-reducing surgery offered | – | – | Moderate | |
| Thyroid cancer | Ultrasound | Yearly | 18a | Strong |
| Renal cancer | Ultrasound | Every 2 years | 40 | Moderate |
| Colorectal cancer | Baseline colonoscopyb | – | 35–40 | Moderate |
| Melanoma | Baseline skin examinationc | – | 30 | Weak |
| Endometrial cancer | Not recommendedd | – | – | Weak |
aModerate evidence for age of commencement of surveillance.
bConsider further surveillance as required by the gastroenterologist.
cConsider further surveillance as required by the dermatologist.
dConsider surveillance as part of clinical trial.